Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–646 of 646 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lacrimal Apparatus Diseases Clear all
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment

NCT04343287
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
BRM421, Placebo
Drug
Lead sponsor
BRIM Biotechnology Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 30, 2026, 1:32 PM EDT
Completed Phase 3 Interventional

A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease

NCT07284381
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ABBV-444, REFRESH OPTIVE UD
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Dothan, Alabama • Chandler, Arizona • Azusa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 30, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants

NCT05878067
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
ABBV-444
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 30, 2026, 1:32 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye

NCT00799552
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RX-10045, Placebo
Drug
Lead sponsor
Resolvyx Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2010 · Synced Oct 30, 2026, 1:32 PM EDT
Terminated Early Phase 1 Interventional

COVID-19 Vaccination in Rheumatic Disease Patients

NCT04839315
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Sjogren's Syndrome, Inflammatory Myositis, Psoriatic Arthritis, Gout, Ankylosing Spondylitis, Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis), Osteoarthritis
Interventions
mRNA COVD19 vaccine
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 30, 2026, 1:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

UNITY DX Cornea Study

NCT07768735
View directory record Official record
Conditions
Tomography
Interventions
UNITY DX, ANTERION
Device
Lead sponsor
Alcon Research
Industry
Eligibility
22 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 1:32 PM EDT
Withdrawn Phase 2 Interventional

Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study

NCT02027298
View directory record Official record
Conditions
Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome, Inflammatory Arthritis, Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 30, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

NCT06660290
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, Artificial tears
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
6
States / cities
Newport Beach, California • Colorado Springs, Colorado • Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 30, 2026, 1:32 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

NCT05848128
View directory record Official record
Conditions
Dry Eye Syndromes, Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions
5% Tavilermide ophthalmic solution, Vehicle ophthalmic solution
Drug · Other
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
29
States / cities
Phoenix, Arizona • Glendale, California • Murrieta, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 30, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients

NCT01276223
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Difluprednate 0.05% ophthalmic emulsion, Difluprednate vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Oct 30, 2026, 1:32 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

NCT05145959
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions
Maskin Probe
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 30, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Systane Ultra Versus Maxidex Versus Saline

NCT01775540
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Systane Ultra, Saline solution, Maxidex
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 30, 2026, 1:32 PM EDT
Completed Phase 4 Interventional

A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens

NCT01061268
View directory record Official record
Conditions
Dry Eye
Interventions
No topical artificial tear, Blink® Tears Lubricant Eye Drops
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 30, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

NCT02040623
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo Ophthalmic Solution
Drug · Other
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Plantation, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 30, 2026, 1:32 PM EDT
Completed Not applicable Interventional Results available

Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator

NCT02526290
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
Intranasal Lacrimal Neurostimulator (Oculeve)
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Phoenix, Arizona • Andover, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 30, 2026, 1:32 PM EDT
Completed Not applicable Interventional Results available

IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD

NCT02066051
View directory record Official record
Conditions
GVHD, Ocular Rosacea, Dry Eye Syndrome
Interventions
IPL, Meibomian Gland Expression
Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 30, 2026, 1:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Point of Care Testing of Inflammatory Markers in Tears

NCT02315079
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Eye inflammation, Without eye inflammation
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 30, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Results available

Effects of NOV03 on the Tear Film

NCT05723770
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
instillation of NOV03
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 30, 2026, 1:32 PM EDT
Completed No phase listed Observational

Tear Dynamics After Restasis Treatment in Dry Eye Patients

NCT00706940
View directory record Official record
Conditions
Dry Eye
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 30, 2026, 1:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tear Film Stability After Instillation of Over-the-Counter (OTC) Artificial Drops

NCT00610480
View directory record Official record
Conditions
Dry Eye Disease
Interventions
1st visit Optive, then 2nd visit Systane, 1st visit Systane, then 2nd visit Optive
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 30, 2026, 1:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lipiflow vs iLux Patient Acceptance and Comfort Study

NCT04454983
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye
Interventions
Lipiflow Thermal Pulsation System, iLux System
Device
Lead sponsor
Epstein, Arthur B., OD, FAAO
Individual
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 30, 2026, 1:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease

NCT05586152
View directory record Official record
Conditions
Dry Eye Disease
Interventions
INV-102, Vehicle
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rush, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 30, 2026, 1:32 PM EDT